MYOV News and Press, Myovant Sciences Ltd. From 03/10/20

BASEL, Switzerland, March 10, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced the cancellation of its presentation and webcast at the Barclays Global Healthcare C...

Myovant Sciences (NYSE: MYOV ) has submitted a marketing application in Europe seeking approval to use a combination tablet formulation of relugolix (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) to treat women with moderate-to-severe symptoms associated with uterine...

If approved, relugolix combination tablet would offer a one pill, once-a-day treatment option for women with uterine fibroids New Drug Application to the U.S. Food and Drug Administration planned for submission in April 2020 BASEL, Switzerland, March 09, 2020 (GLOBE NEWSWIRE) -- ...

BASEL, Switzerland, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant’s CEO, will present at the following investor c...

Originally posted on Reddit Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Myovant Sciences (NYSE: MYOV) reported positive results from the late-stage Liberty extension study testing its relugolix combination therapy, which contains relugolix, estradiol, and norethindrone acetate, in patients with uterine fibroids. The biotech had already successfully tested rel...

vTv Therapeutics (NASDAQ: VTVT ) +80%  on positive TTP399 data . More news on: vTv Therapeutics Inc., Taubman Centers, Inc., Edgewell Personal Care Company, Stocks on the move, Read more ...

Today, we will study why Myovant Sciences ( MYOV ) is a promising pick for 2020. Company overview Myovant Sciences is close to transforming from a clinical-stage biopharmaceutical company to a commercial organization. The company is focused on evaluating its lead asset, Relugolix in comb...

Bluebird bio (NASDAQ: BLUE ) initiated with Buy rating and $120 (56% upside) price target at Bank of America. Upgraded to Outperform with a $100 price target at Evercore ISI. Shares up  2%  premarket. More news on: bluebird bio, Inc., Centene Corporation, Myovant Sciences Ltd., H...

Myovant Sciences ( MYOV ) was founded in 2016 and is based in Brisbane, CA, and Basel, Switzerland. The company's pipeline is focused on the diseases of women's health. The key flagship molecule is Relugolix, a direct antagonist of Gonadotropin-releasing hormone, GnRH. It is already available ...